Bionano Genomics (BNGO) Return on Capital Employed (2018 - 2026)

Bionano Genomics has disclosed Return on Capital Employed across 9 years of filings, most recently posting 68.32% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 68.32%, down 6664.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 68.32% (down 6664.0% YoY), and the FY2025 annual result was 63.89%, down 4215.0% from the prior year.
• Return on Capital Employed came in at 68.32% for Q1 2026 at Bionano Genomics, down from 62.45% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 80.14% in Q3 2025 to a low of 219.36% in Q4 2023.
• The 5-year median for Return on Capital Employed is 53.34% (2023), against an average of 70.02%.
• Across the five-year window, Return on Capital Employed slumped 17227 bps in 2023 and surged 23528 bps in 2025, its largest moves.
• Bionano Genomics' Return on Capital Employed stood at 47.08% in 2022, then tumbled by 366 bps to 219.36% in 2023, then soared by 76 bps to 52.64% in 2024, then decreased by 19 bps to 62.45% in 2025, then declined by 9 bps to 68.32% in 2026.
• The last three Return on Capital Employed figures came in at 68.32% (Q1 2026), 62.45% (Q4 2025), and 80.14% (Q3 2025), per Business Quant data.